Sponsored Links
| Phase 3 Lymphoseek (Tilmanocept) Study Results Featured At Society Of Nuclear Medicine Annual Meeting |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek® (99mTc-tilmanocept) met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures... Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|